187 related articles for article (PubMed ID: 29348684)
1. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.
Liu R; Zhi X; Zhou Z; Zhang H; Yang R; Zou T; Chen C
Sci Rep; 2018 Jan; 8(1):1138. PubMed ID: 29348684
[TBL] [Abstract][Full Text] [Related]
2. Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression.
Liu R; Shi P; Nie Z; Liang H; Zhou Z; Chen W; Chen H; Dong C; Yang R; Liu S; Chen C
Theranostics; 2016; 6(4):533-44. PubMed ID: 26941846
[TBL] [Abstract][Full Text] [Related]
3. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.
Zhou W; Song F; Wu Q; Liu R; Wang L; Liu C; Peng Y; Mao S; Feng J; Chen C
PLoS One; 2017; 12(4):e0176395. PubMed ID: 28437471
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
[TBL] [Abstract][Full Text] [Related]
5. The Curcumin Analog EF24 Inhibits Proliferation and Invasion of Triple-Negative Breast Cancer Cells by Targeting the Long Noncoding RNA HCG11/Sp1 Axis.
Duan Y; Chen HL; Ling M; Zhang S; Ma FX; Zhang HC; Lv XA
Mol Cell Biol; 2022 Jan; 42(1):e0016321. PubMed ID: 34780286
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
[TBL] [Abstract][Full Text] [Related]
8. Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.
Zhang QQ; Chen J; Zhou DL; Duan YF; Qi CL; Li JC; He XD; Zhang M; Yang YX; Wang L
Int J Biol Sci; 2017; 13(4):471-479. PubMed ID: 28529455
[TBL] [Abstract][Full Text] [Related]
9. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
10. Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis.
Liu R; Chen H; Zhao P; Chen CH; Liang H; Yang C; Zhou Z; Zhi X; Liu S; Chen C
Int J Biol Sci; 2020; 16(4):611-619. PubMed ID: 32025209
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
14. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
Yuan P; Wang L; Wei D; Zhang J; Jia Z; Li Q; Le X; Wang H; Yao J; Xie K
Cancer; 2007 Dec; 110(12):2682-90. PubMed ID: 17973266
[TBL] [Abstract][Full Text] [Related]
16. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
17. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
19. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
20. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
